Headquartered in The Woodlands, TX·Fiscal year ends December·NASDAQ: LXRX·lexpharma.com
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a biopharmaceutical company developing novel medicines for serious cardiometabolic diseases, building on its legacy in genetic target discovery.
Its lead asset is sotagliflozin, an oral dual SGLT1/SGLT2 inhibitor studied in about 20,000 patients:
- Marketed in the U.S. for heart failure as INPEFA.
- In the pivotal Phase 3 SONATA-HCM trial for obstructive and non-obstructive hypertrophic cardiomyopathy.
- Planned for an NDA resubmission as ZYNQUISTA for glycemic control in adults with type 1 diabetes.
Viatris holds the sotagliflozin license for all indications outside the U.S. and Europe.
Lexicon has licensed LX9851, a first-in-class oral non-incretin ACSL5 inhibitor for obesity, to Novo. That deal carries up to $1 billion in potential milestones (of which $75 million has been earned) plus tiered royalties.
It is also developing pilavapadin (LX9211), a once-daily oral AAK1 inhibitor that is Phase 3-ready for diabetic peripheral neuropathic pain and being explored in obesity.
Revenue currently comes mainly from licensing and milestone payments, plus modest INPEFA product sales. Updated
Penny stocks represent an interesting investment opportunity. These stocks typically represent small companies or companies that are early in the development stages. But isn’t that how you make it big in the…
Friday's additional top analyst upgrades and downgrades were on Ciena, Lennar, Lexicon Pharmaceuticals, Mister Car Wash, PagerDuty, RealReal, Six Flags and more.
Lexicon Pharma shares jumped on Thursday morning after the company announced that it received regulatory feedback from the FDA regarding its heart failure treatment.
Lexicon shares jumped on Friday after the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion on the Marketing Authorization of Zynquista (sotagliflozin).
Lexicon shares fell on Friday after the FDA voted to approve the firm’s type 1 diabetes treatment. Although the result from this committee was mixed, it seems to be a case of…
The top analyst upgrades, downgrades and other research calls from Monday include American Electric Power, American Water Works, BHP Billiton, Boeing, Costco, Crocs, Dollar General, McDonald's and Ulta Beauty.
Lexicon Pharmaceuticals is a biopharmaceutical company developing novel medicines for serious cardiometabolic diseases, building on its legacy in genetic target discovery.
What is the LXRX stock price target?
The Wall Street consensus 12-month price target for LXRX is $4.52.